JP2015502387A5 - - Google Patents

Download PDF

Info

Publication number
JP2015502387A5
JP2015502387A5 JP2014548061A JP2014548061A JP2015502387A5 JP 2015502387 A5 JP2015502387 A5 JP 2015502387A5 JP 2014548061 A JP2014548061 A JP 2014548061A JP 2014548061 A JP2014548061 A JP 2014548061A JP 2015502387 A5 JP2015502387 A5 JP 2015502387A5
Authority
JP
Japan
Prior art keywords
hal
formula
alkyl
independently
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014548061A
Other languages
English (en)
Japanese (ja)
Other versions
JP6129203B2 (ja
JP2015502387A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/076595 external-priority patent/WO2013092979A1/en
Publication of JP2015502387A publication Critical patent/JP2015502387A/ja
Publication of JP2015502387A5 publication Critical patent/JP2015502387A5/ja
Application granted granted Critical
Publication of JP6129203B2 publication Critical patent/JP6129203B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014548061A 2011-12-22 2012-12-21 α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤 Expired - Fee Related JP6129203B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161579076P 2011-12-22 2011-12-22
US61/579,076 2011-12-22
EP11195107 2011-12-22
EP11195107.5 2011-12-22
PCT/EP2012/076595 WO2013092979A1 (en) 2011-12-22 2012-12-21 Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors

Publications (3)

Publication Number Publication Date
JP2015502387A JP2015502387A (ja) 2015-01-22
JP2015502387A5 true JP2015502387A5 (cg-RX-API-DMAC10.html) 2016-02-18
JP6129203B2 JP6129203B2 (ja) 2017-05-17

Family

ID=48667763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548061A Expired - Fee Related JP6129203B2 (ja) 2011-12-22 2012-12-21 α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤

Country Status (15)

Country Link
US (1) US9688702B2 (cg-RX-API-DMAC10.html)
EP (1) EP2793900B1 (cg-RX-API-DMAC10.html)
JP (1) JP6129203B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140114391A (cg-RX-API-DMAC10.html)
CN (1) CN104321060B (cg-RX-API-DMAC10.html)
AU (1) AU2012356890B2 (cg-RX-API-DMAC10.html)
BR (1) BR112014015363A8 (cg-RX-API-DMAC10.html)
CA (1) CA2860142C (cg-RX-API-DMAC10.html)
EA (1) EA201400735A1 (cg-RX-API-DMAC10.html)
ES (1) ES2699267T3 (cg-RX-API-DMAC10.html)
HK (1) HK1206261A1 (cg-RX-API-DMAC10.html)
IL (1) IL233200A (cg-RX-API-DMAC10.html)
MX (1) MX352652B (cg-RX-API-DMAC10.html)
SG (2) SG10201605152SA (cg-RX-API-DMAC10.html)
WO (1) WO2013092979A1 (cg-RX-API-DMAC10.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2599791C2 (ru) 2010-08-10 2016-10-20 Ремпекс Фармасьютикэлз, Инч. Циклические бороновые кислотно-эфирные производные и их использование в терапии
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2015006715A (es) 2012-12-03 2015-08-14 Hoffmann La Roche Compuestos de acido triazolboronico sustituido.
JP6403219B2 (ja) 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2014204045B2 (en) * 2013-01-04 2018-10-18 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR20150103270A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
CN105101970B (zh) 2013-01-10 2018-11-20 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
ES2748434T3 (es) 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
WO2015171398A1 (en) 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
US10385074B2 (en) 2014-05-05 2019-08-20 Rempex Pharmaceuticals, Inc. Synthesis of boronate salts and uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
KR102396753B1 (ko) 2014-06-11 2022-05-12 베나토알엑스 파마슈티컬스, 인크. 베타-락타마제 억제제
AU2015284307A1 (en) * 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US11202817B2 (en) 2014-08-18 2021-12-21 Cornell University Dipeptidomimetics as inhibitors of human immunoproteasomes
EP3201207B1 (en) * 2014-10-01 2021-02-24 Merck Patent GmbH Boronic acid derivatives
EP3201208B1 (en) * 2014-10-01 2021-03-24 Merck Patent GmbH Boronic acid derivatives
US10640520B2 (en) * 2014-10-01 2020-05-05 Merck Patent Gmbh Boronic acid derivatives
AU2015327345B9 (en) 2014-10-01 2020-06-18 Merck Patent Gmbh Boronic acid derivatives
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP3347008B1 (en) 2015-09-11 2022-03-09 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP4006012A1 (en) 2015-10-15 2022-06-01 Cornell University Proteasome inhibitors and uses thereof
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
AU2017290060B2 (en) 2016-06-30 2021-07-22 Qpex Biopharma, Inc Boronic acid derivatives and therapeutic uses thereof
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3630782A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
IL272806B2 (en) 2017-08-24 2023-09-01 Merck Patent Gmbh The history of boronic acid, its preparation and pharmaceutical preparations containing it
WO2019075252A1 (en) 2017-10-11 2019-04-18 Cornell University PEPTIDOMIMETIC INHIBITORS OF PROTEASOME
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
CN107556336A (zh) * 2017-10-16 2018-01-09 康化（上海）新药研发有限公司 一种呋喃‑2‑甲烷基硼酸频哪醇酯的合成方法
WO2019099582A1 (en) 2017-11-16 2019-05-23 Principia Biopharma Inc. Immunoproteasome inhibitors
PL3710457T3 (pl) 2017-11-16 2023-02-20 Principia Biopharma Inc. Inhibitory immunoproteasomu
CN108130370B (zh) * 2018-01-05 2020-11-17 武汉惠康达科技有限公司 Psmb8及其抑制剂在制备治疗脂肪肝及其相关疾病药物中的应用
CN112424209A (zh) 2018-04-20 2021-02-26 Qpex生物制药有限公司 硼酸衍生物及其治疗用途
US12173018B2 (en) 2018-05-25 2024-12-24 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
MX2021000214A (es) 2018-07-26 2021-03-31 Merck Patent Gmbh Derivados de acido boronico.
DK3886798T3 (da) 2018-11-29 2026-04-20 Basilea Pharmaceutica Int Ag Allschwil Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf
US12636297B2 (en) 2019-06-19 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
US12637481B2 (en) 2020-03-18 2026-05-26 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
IL297458A (en) 2020-05-05 2022-12-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses
CN114075227B (zh) * 2020-08-19 2023-07-04 北京嵩润医药科技有限责任公司 吡唑硼酸类化合物、包含其的药物组合物及它们的用途
US20250340577A1 (en) * 2021-03-02 2025-11-06 Case Western Reserve University Beta-lactomase inhibitors and uses thereof
CN116940580A (zh) * 2021-03-05 2023-10-24 Ａｇｃ株式会社 化合物、化合物的制造方法及表面处理剂的制造方法
US20240287102A1 (en) 2021-07-29 2024-08-29 Merck Patent Gmbh Novel crystalline forms of [(1r)-2-(1-benzofuran-3-yl)-1-{[(1s,2r,4r)-7-oxabicyclo[2.2.1]heptan-2-yl]formamido}ethyl]boronic acid, adducts thereof, and processes to obtain
JP7734276B2 (ja) * 2021-10-14 2025-09-04 ショウヤオ ホールディングス（ベイジン） カンパニー， リミテッド ボロン酸誘導体
CN117003776A (zh) * 2022-04-29 2023-11-07 科辉智药生物科技(深圳)有限公司 一种硼酸类蛋白酶体抑制剂及其用途
WO2023232830A1 (en) 2022-06-02 2023-12-07 Merck Patent Gmbh Boronic acid adducts
CN122374318A (zh) 2023-11-21 2026-07-10 巴斯利尔药物阿尔施维尔国际股份公司 口服递送的β-内酰胺酶抑制剂的柠檬酸盐配位复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111175A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
US7332343B2 (en) * 2004-01-16 2008-02-19 Board Of Regents, The University Of Texas System Determining enantiomeric excess using indicator-displacement assays
ES2899606T3 (es) * 2004-03-30 2022-03-14 Millennium Pharm Inc Síntesis de compuestos de ésteres y ácidos borónicos
WO2008060488A1 (en) 2006-11-14 2008-05-22 Merck & Co., Inc. Tricyclic heteroaromatic compounds as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
KR20140042933A (ko) * 2007-08-06 2014-04-07 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아좀 억제제
EP2212334B1 (en) * 2007-10-16 2012-08-15 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
EA201000774A1 (ru) * 2007-11-13 2010-12-30 Новартис Интернэшнл Фармасьютикл Лтд. Ингибиторы бета-лактамазы
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
AU2011235227B2 (en) * 2010-03-31 2016-09-08 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US8507494B2 (en) 2010-04-30 2013-08-13 Merck Sharp & Dohme Corp. Heterocyclic quinolizine derived M1 receptor positive allosteric modulators

Similar Documents

Publication Publication Date Title
JP2022541467A (ja) オーロラキナーゼ阻害剤およびその使用
ES2643379T3 (es) Nuevas dihidropirimidinoisoquinolinonas y sus composiciones farmacéuticas para el tratamiento de trastornos inflamatorios
JP2009524691A5 (cg-RX-API-DMAC10.html)
JP2017511357A5 (cg-RX-API-DMAC10.html)
JP2018537483A (ja) ビアリールモノバクタム化合物および細菌感染治療のためのそれの使用方法
JP2016534146A5 (cg-RX-API-DMAC10.html)
KR20170049604A (ko) Bub1 억제제로서의 벤질 치환된 인다졸
JP2008503591A5 (cg-RX-API-DMAC10.html)
JP2015163632A5 (cg-RX-API-DMAC10.html)
BR112015023142B1 (pt) Moduladores do p2x7, seu uso, processo de preparação e composição farmacêutica que os compreende
CA2952307A1 (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
JP2013536259A5 (cg-RX-API-DMAC10.html)
JP2015501327A5 (cg-RX-API-DMAC10.html)
KR20210005668A (ko) Hpk1 억제제, 그의 제조 방법 및 응용
EP2001872A1 (en) Benzofuran compounds as ep1 receptor antagonists
JP7627008B2 (ja) ピロール化合物
WO2012098033A1 (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
EA030410B1 (ru) Замещенные конденсированные гетероциклы в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных нарушений
JP2022529311A5 (cg-RX-API-DMAC10.html)
JP2016532669A5 (cg-RX-API-DMAC10.html)
JP2025500886A5 (cg-RX-API-DMAC10.html)
JP2014505033A5 (cg-RX-API-DMAC10.html)
JP2019532092A5 (cg-RX-API-DMAC10.html)
JP2010518146A (ja) ベンゾフラン化合物
AU2009335159B2 (en) Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid